Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lavage

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    167 result(s) found for: Lavage. Displaying page 4 of 9.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2020-001963-10 Sponsor Protocol Number: 2020-CHITS-003 Start Date*: 2020-05-12
    Sponsor Name:Centre Hospitalier Intercommunal de Toulon La Seyne-sur-mer
    Full Title: Interleukin-1 (IL-1) and Interferon gamma (IFNg) inhibition during COVID 19 inflammation: Randomized, controlled study assessing efficacy and safety of Anakinra and Ruxolitinib
    Medical condition: Covid-19 disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006809-29 Sponsor Protocol Number: N21CCI Start Date*: 2022-05-23
    Sponsor Name:NKI-AVL
    Full Title: Body surface area-based vs concentration-based dosing of cisplatin for hyperthermic intraperitoneal chemotherapy (HIPEC) in women with advanced ovarian cancer
    Medical condition: FIGO stage III high grade serous ovarian cancer, peritoneal cancer, or fallopian tube carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001169-18 Sponsor Protocol Number: UoL001360 Start Date*: 2018-10-15
    Sponsor Name:University Of Liverpool
    Full Title: The efficacy and mechanism of surfactant therapy for critically ill infants with bronchiolitis: The Bronchiolitis Endotracheal Surfactant Study.
    Medical condition: Critical Illness due to Bronchiolitis of infancy requiring conventional invasive Mechanical Ventilation (MV) Diagnosis of bronchiolitis per clinical criteria defined in national guidance NICE-NG9.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10038718 Respiratory syncytial virus bronchiolitis PT
    20.1 10021881 - Infections and infestations 10065188 Lower respiratory tract infection viral PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-015785-64 Sponsor Protocol Number: PRODIGE 11/FFCD 0803 Start Date*: 2009-11-17
    Sponsor Name:CHU de DIJON - Délégation à la recherche clinique et à l’innovation
    Full Title: ESSAI RANDOMISE - SORAFENIB-PRAVASTATINE VERSUS SORAFENIB SEUL POUR LE TRAITEMENT PALLIATIF DU CARCINOME HEPATOCELLULAIRE CHILD-PUGH A
    Medical condition: Carcinome hépatocellulaire (CHC) non accessible à un traitement à visée curative
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-005787-22 Sponsor Protocol Number: EP395-003 Start Date*: 2022-07-21
    Sponsor Name:EpiEndo Pharmaceuticals
    Full Title: A randomised, double-blind, placebo-controlled study to investigate the safety and tolerability of EP395 in patients with chronic obstructive pulmonary disease (COPD)
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004154-22 Sponsor Protocol Number: TR701-132 Start Date*: 2014-04-17
    Sponsor Name:Trius Therapeutics, a Wholly Owned Subsidiary of Cubist Pharmaceuticals, Inc.
    Full Title: A Phase 3 Randomized Double-blind Study Comparing TR 701 FA and Linezolid in Ventilated Gram-positive Nosocomial Pneumonia
    Medical condition: Ventilated Gram-positive nosocomial pneumonia
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004862 10052596 Nosocomial pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) AT (Completed) DE (Completed) BE (Completed) ES (Completed) GR (Completed) SK (Completed) CZ (Completed) EE (Completed) GB (Completed) HR (Completed) PT (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002862-11 Sponsor Protocol Number: CXA-NP-11-04 Start Date*: 2015-07-27
    Sponsor Name:Cubist Pharmaceuticals GmbH
    Full Title: A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/tazobactam Compared With Meropenem in Adult Patients with Ventilated...
    Medical condition: Ventilated Nosocomial Pneumonia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10052596 Nosocomial pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) EE (Completed) DE (Completed) BE (Completed) LV (Completed) CZ (Completed) HU (Completed) SK (Completed) AT (Completed) GR (Completed) PT (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004854-97 Sponsor Protocol Number: A8851019 Start Date*: 2008-01-15
    Sponsor Name:Pfizer Ltd
    Full Title: OPEN-LABEL, NON-COMPARATIVE, STUDY OF INTRAVENOUS ANIDULAFUNGIN, FOLLOWED OPTIONALLY BY ORAL VORICONAZOLE OR FLUCONAZOLE THERAPY, FOR TREATMENT OF DOCUMENTED CANDIDEMIA/INVASIVE CANDIDIASIS IN INTE...
    Medical condition: CANDIDAEMIA/INVASIVE CANDIDIASIS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064954 Invasive candidiasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) FR (Completed) BE (Completed) PT (Completed) NL (Completed) IT (Completed) SK (Completed) PL (Completed) CZ (Completed) DK (Completed) HU (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002146-23 Sponsor Protocol Number: ASN100-201 Start Date*: 2017-01-19
    Sponsor Name:Arsanis, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Single Dose of ASN100 for the Prevention of Staphylococcus aureus Pneumonia in Heavily Coloni...
    Medical condition: Prevention of Staphylococcus aureus Pneumonia in Heavily Colonized, Mechanically Ventilated Subjects
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Completed) DE (Prematurely Ended) ES (Completed) PT (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018724-16 Sponsor Protocol Number: AZI002 Start Date*: 2010-04-15
    Sponsor Name:KULeuven and University Hospitals Leuven (Leuven Lung Transplant Group)
    Full Title: A prospective, open-label, pilot-study of azithromycin for lymphocytic bronchi(oli)tis after lung transplantation
    Medical condition: Lymphocytic airway inflammation (so-called Lymphocytic Bronchitis or Bronchiolitis) post-lung transplantation: evolution of airway inflammation (BAL, TBB), pulmonary function, radiology after 3 mon...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006414 Bronchial biopsy abnormal LLT
    12.1 10025041 Lung biopsy abnormal LLT
    12.1 10063078 Bronchoalveolar lavage abnormal LLT
    12.1 10049083 Respiratory tract infection NOS LLT
    12.1 10016547 FEV LLT
    12.1 10016549 FEV 1 abnormal LLT
    12.1 10016550 FEV 1 decreased LLT
    12.1 10016553 FEV 1 low LLT
    12.1 10057799 Computerised tomogram thorax abnormal LLT
    12.1 10025127 Lung transplant LLT
    12.1 10056409 Heart and lung transplant LLT
    12.1 10051604 Lung transplant rejection LLT
    12.1 10019319 Heart-lung transplant rejection LLT
    12.1 10029888 Obliterative bronchiolitis LLT
    12.1 10049202 Bronchiolitis obliterans LLT
    12.1 10050433 Prophylaxis against lung transplant rejection LLT
    12.1 10050437 Prophylaxis against heart and lung transplant rejection LLT
    12.1 10066543 Acute allograft rejection LLT
    12.1 10049237 Acute cellular rejection LLT
    12.1 10039008 Reversible airways obstruction NOS LLT
    12.1 10039008 Reversible airways obstruction NOS LLT
    12.1 10068956 Respiratory tract inflammation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000138-11 Sponsor Protocol Number: PIPF-006 Start Date*: 2006-05-23
    Sponsor Name:InterMune, Inc.
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiophatic Pulmonary Fibrosis
    Medical condition: Idiophatic Pulmonary Fibrosis (IPF)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) DE (Completed) BE (Completed) CZ (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-002000-32 Sponsor Protocol Number: CTBM100C2401 Start Date*: 2011-11-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A single arm, open-label, multicenter, Phase IV trial to assess long term safety of tobramycin inhalation powder (TIP) in patients with Cystic Fibrosis
    Medical condition: Pseudomonas aeruginosa infection in cystic fibrosis patients
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10021860 Infection pseudomonas aeruginosa LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FR (Ongoing) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005278-11 Sponsor Protocol Number: A8851022 Start Date*: 2009-03-06
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: EFFICACY AND SAFETY OF ERAXIS™/ECALTA® (ANIDULAFUNGIN) COMPARED TO CANCIDAS® (CASPOFUNGIN) IN PATIENTS WITH CANDIDA DEEP TISSUE INFECTION
    Medical condition: INVASIVE CANDIDIA INFECTIONS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064954 Invasive candidiasis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) BE (Prematurely Ended) IE (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000441-20 Sponsor Protocol Number: TR02-108 Start Date*: 2011-06-29
    Sponsor Name:Insmed Incorporated
    Full Title: Randomized, open-label, active-controlled, multicenter study to assess the efficacy, safety and tolerability of Arikace™ in Cystic Fibrosis patients with chronic infection due to Pseudomonas aerug...
    Medical condition: Pseudomonas aeruginosa pulmonary infection / colonisation in patients with cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10011763 Cystic fibrosis lung PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) BE (Completed) IE (Completed) DE (Completed) AT (Completed) GR (Completed) NL (Completed) DK (Completed) ES (Completed) IT (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2011-000442-38 Sponsor Protocol Number: TR02-109 Start Date*: 2011-10-03
    Sponsor Name:Insmed Incorporated
    Full Title: Randomized, placebo-controlled, double-blind, multicenter study to assess the efficacy, safety and tolerability of Arikace™ in Cystic Fibrosis patients with chronic infection due to Pseudomonas Aer...
    Medical condition: Pseudomonas aeruginosa pulmonary infection / colonisation in patients with cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10011763 Cystic fibrosis lung PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) PL (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000476-18 Sponsor Protocol Number: SPX-CF-001 Start Date*: 2022-05-24
    Sponsor Name:EnBiotix, Inc.
    Full Title: Tolerability and Safety of Inhaled Colistimethate Sodium Administered Once Daily Compared to Twice Daily Dosing in Adult and Adolescent Subjects with Cystic Fibrosis and Chronic Pseudomonas Aerugin...
    Medical condition: Chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011763 Cystic fibrosis lung PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Ongoing) SK (Prematurely Ended) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002555-10 Sponsor Protocol Number: ORCA2015 Start Date*: 2015-11-19
    Sponsor Name:Imperial College
    Full Title: Effect of the CRTH2 antagonist OC459 on the response to rhinovirus challenge in asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000015470 10001705 Allergic asthma LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    20.0 100000022885 10049868 Asthma exacerbation prophylaxis LLT
    20.0 100000015470 10003638 Atopic asthma LLT
    20.0 100000015470 10015575 Exacerbation of asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-014412-35 Sponsor Protocol Number: ARD-3100-0901 Start Date*: 2010-02-23
    Sponsor Name:Aradigm Corporation
    Full Title: An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Administration of Two Strengths of Ciprofloxacin f...
    Medical condition: Non-cystic fibrosis bronchiectasis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10006446 Bronchiectasis NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021574-11 Sponsor Protocol Number: 32729463CAP2001 Start Date*: 2011-01-24
    Sponsor Name:Furiex Pharmaceuticals, Inc
    Full Title: A Randomized, Controlled, Double-Blind, Multicenter, Phase 2 Study of the Safety/Tolerability and Efficacy of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospita...
    Medical condition: Community-Acquired Bacterial Pneumonia (CABP)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10004051 Bacterial pneumonia, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-000252-41 Sponsor Protocol Number: PIPF-004 Start Date*: 2006-06-29
    Sponsor Name:InterMune, Inc.
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Phase 3 Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
    Medical condition: Idiopathic Pulmonary Fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021240 Idiopathic pulmonary fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 00:18:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA